Pfizer starts early-stage trial of combined Covid and flu vaccine
The trial will look at the safety of the combined jab, how effective it is and whether patients suffer any side-effects
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Pharmaceutical giant Pfizer has launched an early-stage study of a combined Covid/flu vaccine.
The firm, which is partnering with BioNTech, said the first patient was given a dose this week of the vaccine, which combines a flu shot and Pfizer’s bivalent Covid vaccine designed to tackle the Omicron variant.
The phase 1 study, to be carried out in the US, is recruiting 180 people aged 18 to 64, who will be followed up for six months.
The study will look at the safety of the combined jab, how effective it is and also whether patients suffer any side-effects.
The flexibility and manufacturing speed of the mRNA technology has demonstrated that it is well-suited for other respiratory diseases
Annaliesa Anderson, chief scientific officer in vaccine research and development at Pfizer, said the vaccine was based on the mRNA technology used for Pfizer’s pandemic jab.
“The flexibility and manufacturing speed of the mRNA technology has demonstrated that it is well-suited for other respiratory diseases,” she said.
“Pfizer is deeply proud of our continued work to explore its potential to protect against influenza and Covid-19 in one combination vaccine, which we think could simplify immunisation practices against these two respiratory pathogens, potentially leading to better vaccine uptake for both diseases.
“Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalisations every year.
“This is an exciting step in our ongoing journey with BioNTech as we collectively look to transform the prevention of infectious diseases around the world.”